CRISPR Therapeutics reported its financial results for the first quarter ended March 31, 2025, with a quarterly loss of $1.58 per share and sales of $865,000. The company maintained a strong balance sheet, holding approximately $1.86 billion in cash, cash equivalents, and marketable securities as of March 31, 2025. This cash position is crucial for funding its extensive research and development activities.
The company announced positive top-line data from its Phase 1 clinical trial of CTX310, an in vivo gene editing therapy targeting ANGPTL3 for cardiovascular disease. The data demonstrated dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reductions of up to 82% in TG and up to 81% in LDL. CTX310 exhibited a well-tolerated safety profile, with no treatment-related severe adverse events or grade ≥3 adverse events reported.
Commercialization efforts for CASGEVY continued to advance, with more than 65 authorized treatment centers activated globally and over 90 patients having undergone cell collection across all regions. This progress indicates ongoing patient access and uptake for the company's first approved CRISPR-based therapy. An update for CTX320, another in vivo program, is on track for the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.